This work represents the first demonstration of PLL-coated PEG-PLGA polymersomes enabling intracellular delivery of full-length antibodies both in vitro and in vivo, establishing a versatile nanoplatform for lung-targeted intracellular antibody therapeutics.
Abstract
The intracellular delivery of full-length antibodies offers substantial therapeutic potential but remains limited by poor cellular uptake, extracellular degradation, and inefficient encapsulation strategies. Here, we report a noninvasive, scalable, and biocompatible nanocarrier platform based on poly-l-lysine (PLL)-coated polyethylene glycol-block-poly(lactic-co-glycolic acid) (PEG-PLGA) polymersomes for efficient intracellular antibody delivery. Coating polymersomes with 30 kDa ε-poly-l-lysine increased antibody encapsulation efficiency to ∼ 80%. It enabled precise modulation of surface charge to a mildly positive ζ-potential (∼+4.5 mV), while maintaining nanoscale dimensions (hydrodynamic diameter ≈ 420 ± 30 nm). The resulting formulation exhibited excellent biocompatibility, preserving >96% cell viability in primary human pulmonary fibroblasts. Importantly, PLL-coated polymersomes facilitated efficient intracellular delivery of full-length antibodies and preserved their biological function, as demonstrated by robust suppression of NOD-like receptor family pyrin domain-containing 3 (NLRP3)-dependent IL-1β signaling. Upon pulmonary administration via aerosolization, polymersomes delivered the antibody efficiently to lung-resident cells in vivo without detectable acute cytotoxicity. To our knowledge, this work represents the first demonstration of PLL-coated PEG-PLGA polymersomes enabling intracellular delivery of full-length antibodies both in vitro and in vivo, establishing a versatile nanoplatform for lung-targeted intracellular antibody therapeutics.
The development of nanoparticle (NP)-based drug delivery systems that combine passive tumor targeting, physiological stability, and therapeutic efficacy remains a key challenge in cancer nanomedicine. Here, we report a pH-responsive peptide-functionalized poly(lactic-co-glycolic acid) (PLGA) NP system designed for canc...
Sylwia A. Dragulska, Mina Poursharifi, Benjamin Lesea-Pringle et al.· Molecules· 0 citations
Gene delivery strategies include two main approaches: viral and nonviral systems to deliver the genetic material to target cells. Although viral vectors have high transfection efficacy, their clinical usage has been limited due to the risks of immunogenicity and mutagenesis. Therefore, nonviral delivery strategies such...
E. Çağlar, Emine Saldamlı· Methods in molecular biology· 0 citations
Poly(lactic-co-glycolic acid) (PLGA) nanocarriers can be engineered by varying polymer architecture, particle dimensions, surface chemistry, ligands, coatings, and cargo; however, biological exposure subsequently remodels the interface encountered by cells and tissues. This narrative review examines how this acquired b...
Hamid Omidian, Nazanin Kianinejad, Luigi X. Cubeddu· Current Issues in Molecular...· 0 citations
Polymersomes are synthetic vesicles capable of encapsulating both hydrophilic and hydrophobic cargo, making them attractive candidates for drug delivery applications. The inherent stability of polymer vesicles, such as poly(butadiene)33-b-poly(ethylene oxide)20 polymersomes, is advantageous for cargo retention, but can...
Sebastian A. Zmijewski, Jesse Cecero, S. O'Malley et al.· ACS Omega· 0 citations
Investigating the release, stability, cellular uptake, and transfection capability of LNPs released from four hydrogel systems representing distinct crosslinking mechanisms shows that hydrogel composition is a critical determinant of mRNA-LNP release, stability, and functional delivery.
Andreas G. Schreiber, Felix Hauswirth, Leon Reger et al.· bioRxiv· 0 citations
This work underscores the advantages of biodegradable nanogel architectures and provides a robust, biosafe, and effective platform for precision cancer nanomedicine featuring controlled drug delivery, boosted therapeutic efficacy, and uncompromised systemic safety.
Safiya Nisar, Chloe Jacobson, Jason Yipp et al.· ACS Nano Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.